James Hu

University of Southern California — United States

Medicine · Health Sciences

19h-index2.7kcitations106works1.62yr avg
OpenAlex↗ORCID↗Google Scholar↗Lab page↗

Accepting Students?

No reports yet. Know if this professor is taking students?

Research Topics

Sarcoma Diagnosis and Treatment(62), Gastrointestinal Tumor Research and Treatment(16), CAR-T cell therapy research(15), Vascular Tumors and Angiosarcomas(15), Testicular diseases and treatments(13)

Publications106 total

Abstract A052: Safety, immunogenicity and resistance of <i>in situ</i> Immunomodulation with CDX-301, radiotherapy, CDX-1140, and Poly-ICLC in patients with unresectable and metastatic solid tumors: a phase 1 trial
Cancer Immunology Research·2026
Safety and efficacy of intratumourally administered INT230-6 in adult patients with advanced solid tumours: results from an open-label phase 1/2 dose escalation study
EBioMedicine·2025Open Access
The Effects and Adverse Reactions of Different Bowel Cleansers on Gut Microbiota After Colonoscopy
The Turkish Journal of Gastroenterology·2025Open Access
A multicenter, randomized, global phase 3 study to assess the efficacy and safety of intratumoral (IT) INT230-6 (SHAO, vinblastine, cisplatin) as monotherapy compared with standard of care systemic chemotherapy in adults with locally recurrent, inoperable, or metastatic soft tissue sarcomas (STS; INVINCIBLE-3).
Journal of Clinical Oncology·2025
A phase 1 trial in progress for in situ immunomodulation with CDX-301, radiation therapy, poly-ICLC, and CDX-1140 in patients with unresectable and metastatic solid tumors.
Journal of Clinical Oncology·2024· 3 cited
Physician Leadership and Burnout: The Need for Agency; a Qualitative Study of an Academic Institution
Journal of Healthcare Leadership·2024· 8 citedOpen Access
Excess intermediate risk nonseminoma and regional lymph node metastases at presentation in patients with Hispanic germ cell tumor.
Journal of Clinical Oncology·2024
P2.31-02 Real-World Survival Outcomes in NSCLC in Adults Ages 50 and Younger at a Large Academic Institution
Journal of Thoracic Oncology·2023Open Access
Atezolizumab for Advanced Alveolar Soft Part Sarcoma
New England Journal of Medicine·2023· 124 citedOpen Access
Phase 1 dose-expansion study of oral TP-1287, a cyclin-dependent kinase 9 (CDK9) inhibitor, in patients with Ewing sarcoma (EWS).
Journal of Clinical Oncology·2023· 3 cited
Distinct molecular features and potential therapeutic strategies for spinal cord gliomas.
Journal of Clinical Oncology·2023
Intratumoral INT230-6 (cisplatin, vinblastine, shao) alone or with ipilimumab prolonged survival with favorable safety in adults with refractory sarcomas.
Journal of Clinical Oncology·2023· 4 cited
Data from Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma
2023Open Access
Table S1 from Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma
2023Open Access
Data from Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma
2023Open Access
Figure S1 from Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma
2023Open Access
Figure S1 from Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma
2023Open Access
Figure S2 from Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma
2023Open Access
Table S1 from Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma
2023Open Access
Figure S3 from Circulating Tumor Cells and Biomarker Modulation with Olaratumab Monotherapy Followed by Olaratumab plus Doxorubicin: Phase Ib Study in Patients with Soft-Tissue Sarcoma
2023Open Access
page 1 of 6Next →

Frequent Co-authors

Melissa Burgess(9), Richard F. Riedel(9), Scott H. Okuno(8), William W. Tseng(8), Tanya B. Dorff(8), David I. Quinn(8), Scott M. Schuetze(7), Steven Attia(7), Dennis A. Priebat(7), Sujana Movva(7), Lara E. Davis(7), Damon R. Reed(7), Denise K. Reinke(7), Sandra P. D’Angelo(6), Laurence H. Baker(6), Robert G. Maki(6), Shreyaskumar Patel(6), Brian Andrew Van Tine(6), Hussein Tawbi(5), Kristi Lara(5)